Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD13-02 CAR-T for r/r CD7+ T-ALL/LBL
NCT05716113Phase 1Completed
- Start
- Feb 2023
- Primary completion
- Aug 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RD13-02 in t-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL). Primary endpoints: Dose-limiting toxicity at 28 days and Maximum Tolerated Dose at 28 days. Started Feb 2023; status: completed.
02
Drugs
RD13-02
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT05716113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05716113.